nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2014 | Letter to the Editor

Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan

verfasst von: Dirk Hasenclever, Lars Kurch, Regine Kluge

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, et al. qPET–a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging 2014;41:1301–8.PubMedCrossRef

Laffon E, Marthan R. Interim FDG-PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging 2014. doi:10.1007/s00259-014-2879-3.PubMed

Laffon E, Lamare F, de Clermont H, Burger IA, Marthan R. Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak. Eur Radiol 2014;24:1964–70. doi:10.1007/s00330-014-3222-x.PubMedCrossRef

Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med 2013;54:677–82.PubMedCrossRef

Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma 2014;55:31–7.PubMedCrossRef

Titel: Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan
verfasst von: Dirk Hasenclever
Lars Kurch
Regine Kluge
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2880-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and “semiquantitative SUVmax” to global disease burden assessment

Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals

EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)

Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

Wieslaw L. Nowinski and Beng Choon Chua (eds): The Human Brain in 1969 Pieces. Structure, Vasculature, Tracts, Cranial Nerves, Systems, Head Muscles, and Glands, Version 2.0